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Abstract

CHARACTERIZATION OF LYSOPHOSPHATIDIC ACID SUBSPECIES USING A NOVEL
HPLC ESI-MS/MS METHOD

A Thesis submitted in partial fulfillment of the requirements for the degree of Masters of
Science at Virginia Commonwealth University.
by

ERIC KYLER MAYTON
University of Virginia, B.S. Chemistry, 2007

Director:
CHARLES CHALFANT, PH.D.
ASSOCIATE PROFESSOR WITH TENURE
DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
RESEARCH CAREER SCIENTIST
HUNTER HOLMES MCGUIRE VAMC

Lysophosphatidic acid (LPA) is a bioactive lipid with a plethora of biological functions,
including roles in cell survival, proliferation, and migration. Although high-performance liquid
chromatography electrospray ionization tandem mass spectrometry (HPLC ESI-MS/MS)
technology has been used to measure the levels of LPA in human blood, serum and plasma,
current methods cannot readily detect the minute levels of LPA from cell culture. In this study, a

x

novel HPLC ESI-MS/MS method with enhanced sensitivity was developed which allows
accurate measurements of LPA levels with a limit of quantitation at approximately 10
femtomoles. The method was validated by quantitation of LPA levels in the media of previously
characterized cell lines ectopically expressing autotaxin. Autotaxin overexpression
induced an increase in several subspecies of LPA while others remained unchanged. Lastly, this
HPLC ESI-MS/MS method was validated via biological assays previously utilized to assay LPA
production. Hence, this new HPLC ESI-MS/MS will allow researchers to measure in vitro LPA
levels and also distinguish between specific LPA subspecies for the delineation of individual
biological mechanisms.
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Introduction

1.1

Discovery of the Biological Activity of LPA
Lysophosphatidic acid (LPA) is a glycerophospholipid is composed of a single, variable

length acyl chain, a glycerol backbone and a phosphate head group.1 LPA had been known as a
key lipid precursor for several decades, but the importance of LPA as a signaling molecule was
not discovered until the mid-1980s. It was at this time when exogenous LPA was found to be the
best and most potent Ca2+ mobilizing agonist and mitogen for quiescent fibroblasts.2 In 1990,
Jalink et. al., showed that LPA concentrations in the low nanomolar range were sufficient to
initiate the mobilization of Ca2+ across the plasma membrane.3 These studies showed the growthfactor-like characteristics of LPA and that LPA had characteristics of a receptor ligand in that it
was active well below its critical micelle concentration and displayed a dose-response
relationship.2,3 The study also demonstrated that the functions of LPA were cell-type specific,
could not be recapitulated by other glycerolipids, and that LPA acted on the outer portion of the
plasma membrane.2,3 These observations led to the conclusion that extracellular LPA interacts
with specific receptors on the plasma membrane to initiate downstream signaling cascades.

1.2

LPA Receptors
In 1996, the first G-protein coupled receptor (GPCR) specific for LPA was discovered. 4

In this study, Hecht et. al. showed the overexpression of the vsg-1 gene resulted in increased cell
rounding when treated with serum or LPA alone but did not increase when treated with other
phospholipids.4 This lead to the classification of the protein product of vsg-1 as a LPA specific
GPCR and the subsequent designation of this protein as LPA1. Shortly thereafter, two other LPA
GPCRs were discovered based on sequence homology and were subsequently named LPA2 and
1

LPA3.5-7 LPA1-3 are classified as members of the 'endothelial differentiation gene' (EDG) family.
More recently, two additional GPCR specific for LPA have been discovered and named LPA4
and LPA5.7-9 LPA4 and LPA5 only share roughly 20% sequence homology to the EDG family
receptors and are more closely related to the members of the purigenic receptor family.
Therefore, they have been classified as members of the 'purinergic' (P2Y) receptors.10 Although
the LPA receptors have varying sequence homologies, they are all Type1, rhodopsin-like GPCRs
that contain seven transmembrane alpha helices and couple to distinct heterotrimeric G-protein
subtypes.7 It is currently believed that there may be up to four more LPA specific receptors, but
more research is necessary to properly characterize these receptors. The distinct coupling of the
established LPA receptors and G-protein subtypes is depicted in Figure 1.
All of the established LPA receptors play important physiological roles. By activating
GPCRs, LPA initiates the downstream signaling cascades depicted in Figure 1. These signaling
cascades have important physiological functions that are outlined in Table 1 and Figure 1. As
these figures clearly demonstrate, LPA plays a variety of important roles that affect normal
biological functions. Since LPA plays many vital roles in human physiology, the dysregulation
of LPA production or binding ability to LPA receptors can result in a variety of pathological
conditions, a sampling of which are listed in Table 2.

2

Figure 1: LPA Receptors and Signaling Pathways
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System
Immune

Phenotype
Dentritic cell function
T cell functions

Roles for LPA signaling
Maturation, chemotaxis
Chemotaxis, apoptosis, trafficking,
cytokine production

Vascular

Vasoregulation

Hypertension, endothelial cell death, loss
of vascular integrity
Vasculature maintenance

Vasculogenesis, Angiogenesis
Reproductive

Embryo implantation
Spermatogenesis

Timing and spacing of implantation
Sperm motility, survival factor for germ
cell

Nervous

Growth/development

Proliferation and differentiation of neural
progenitor cells, neuronal survival,
astrocyte proliferation, neurogenesis
Synapse formation, morphological
changes in neurons and astrocytes
Differentiation of oligodendrocytes,
Schwann cell proliferation, survival, and
morphological changes

Morphology
Myelination

Table 1: Physiological Roles of LPA Signaling (adapted from 11)
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Human pathological conditions associated with LPA dysregulation
Nerve injury
Pulmonary fibrosis
Neuro-inflammation
Renal fibrosis
Schizophrenia
Hepatic fibrosis
Developmental delay
Impaired wound healing
Bipolar disorder
Atherosclerosis
Cancer invasion and migration
Obesity
Osteoarthritis
Asthma

Table 2: Pathophysiological Conditions Associated with LPA Dysregulation (adapted from 11)
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1.3

LPA Synthesis
There are several methods of LPA synthesis (Figure 2), but the major pathways of LPA

production are the cleavage of an acyl chain from phosphatidic acid (PA) via a phospholipase or
the removal of a choline from lysophosphatidylcholine (LPC) by autotaxin.12-14 PLA1 can cleave
an acyl chain from the sn-1 position of PA to produce LPA while PLA2 can cleave an acyl chain
from the sn-2 position of PA to produce LPA.13 Although PLA1 and PLA2 can synthesize LPA,
the major source of LPA production is the cleavage of a choline group from LPC by the enzyme
autotaxin. Autotaxin is synthesized a prepro-enzyme that is proteolyzed by furin-mediated
cleavage and secreted as an activated glycoprotein.15,16 Originally identified as an autocrine
motility factor secreted by melanoma cells, the discovery of the lyso-PLD function of autotaxin
led to a better understanding of LPA production and function. 15, 17-19 The generation of LPA by
autotaxin occurs by the hydrolysis of the choline group at the sn-3 position of
lysophosphatidylcholine (LPC). The human gene that encodes autotaxin, ENPP2, contains 27
exons and has been shown to form three alternatively spliced products.16,20 ATXα, also referred
to as ATXm, is a 915 amino acid protein that lacks exon 21 from ENPP2 gene that was
originally cloned from human melanoma cell line A2058.21 ATXβ, also referred to as ATXt, is a
863 amino acid protein that lacks both exons 12 and 21 from ENPP2 gene and was originally
reported in human tetracarcinoma cells.22 A third, less prominent isoform, ATXγ, also known as
PD-1α, lacks exon 12 and seems to be brain-specific.23 While the ability of autotaxin to produce
LPA has been widely established, the specific LPA species produced by autotaxin isoforms is
not well understood. Furthermore, the differential biological functions for the individual LPA
subspecies have not been examined, mainly due to a lack of reliable method to analyze and
quantitate LPA subspecies in vitro.
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Figure 2: Routes of LPA Production. (H - head group, P - phosphate)
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1.4

Lipid Extractions
Due to their wide variety of characteristics, no single extraction technique is sufficient for

the separation of lipids from biological samples. Extractions protocols should be optimized to
achieve most accurate and highest recovery for the individual lipid of interest. The classical lipid
extraction protocols are liquid-liquid extractions in which lipids separate into the more apolar
solvent. The most common lipid extraction technique was originally devised by Folch, et. al., in
1956 and involves a liquid-liquid extraction using a 2:1 ratio of chloroform:methanol.24 Most
lipids, due to their hydrophobic character, will separate into chloroform phase since it is less
polar than the methanol phase. Bligh and Dyer developed an adaptation of the Folch method to
reduce solvent consumption with the separation again based on the polar character of the
solvents.25 The Bligh-Dyer technique utilizes a chloroform:methanol:water extraction in the ratio
of 1.25:2.5:1 with a centrifugation step to aid in phase separation. Lipids will again separate into
the less polar, chloroform layer.
Numerous adaptations have been made to the Folch and Bligh-Dyer methods for the
extraction of particular lipid classes. One such adaptation was made by Merrill et. al., for
efficient extraction of sphingolipids. This method utilizes a single phase
chloroform:methanol:water solvent combination and an overnight incubation at 48°C in order to
account for the differing polarity among sphingolipids.26 Although lipid-specific adaptations of
the Folch and Bligh-Dyer methods have been the common standard for multiple generations,
many other lipid extractions have recently been popularized, including supercritical fluid
extractions, single solvent extractions, and solid phase extractions (SPE).
Supercritical fluids are gases that approach the density of liquids but have the ability to
diffuse like a gas. Due to its apolar character, supercritical carbon dioxide has been used
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efficiently for the extraction of lipids.27 Although supercritical liquid extractions are
environmentally friendly and can be easily established with simple laboratory apparatus, the
extraction protocol has yet to become a widely used method of lipid extraction. Single solvent
extraction techniques using solvents such as methanol, ethyl acetate, acetonitrile, and methyl
tert-butyl ether have gained popularity because of the simple dilution and centrifugation protocol
they entail.28 These extractions, however, may not provide significant lipid recovery from
samples that contain very low levels of the lipid being analyzed, particularly in vitro samples.
SPE extractions are based on principles of column chromatography where sample is separated
based on its interaction with a stationary phase. SPE lipid extractions typically entail silica-based
columns as stationary phases in order to separate lipids from the more hydrophilic molecules
based on the hydrophobic interactions with the stationary phase.29 While SPE can provide
remarkable recovery of certain lipid classes, the necessity of a separate SPE column for each
sample can become economically unfeasible. As detailed above, no single extraction is sufficient
for all lipids and therefore, several techniques should be tested for the optimal extraction of the
specific lipid of interest.

1.5

Lipidomics
Numerous detection and quantitation methods have been utilized for lipid analysis. After

lipids have been extracted from samples, they must be further separated for accurate analysis. A
classical technique for lipid separation is thin layer chromatography (TLC), a method that
separates compounds based on capillary action in response to their interaction with the stationary
phase.30. High-performance liquid chromatography (HPLC) has replaced TLC as the preferred
method of lipid separation in recent generations.29 HPLC is similar in principle to TLC, as both
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techniques separate lipids based on interaction with a stationary phase, but HPLC has proven to
be a more versatile and more efficient method of separation. One advantage of HPLC separation
of lipids is the ability to quickly and easily utilize different types of stationary phases for
different categories of separation. In normal phase HPLC, lipids are separated based on head
group interaction with a polar stationary phase and elution with a solvent gradient shifting from
apolar to polar. This combination of stationary phase and solvent conditions allows for effective
separation of lipid classes based on the charge of the molecule. Reverse phase chromatography
separates lipids using apolar stationary phase and a solvent gradient that shifts from polar to
apolar. This allows for accurate separation of lipid species based on the degree of hydrophobic
interaction of the sample with an apolar stationary phase. The combination of normal and reverse
phase HPLC in tandem allows for even greater discrimination of lipids based first on the charged
head group and then on hydrophobic acyl chain length.31 The flexibility, increased sensitivity,
and greater technical ease have led to HPLC becoming the preferred method of lipid separation.
Following extraction and separation, lipids can be detected using ultraviolet detection,
immunoassays, radiolabelling, and mass spectrometry. If a lipid contains a chromophore, such as
a conjugated double bond system, it can be measured using ultraviolet detection. In this detection
method, chromatographic solvents selected must not absorb in the ultraviolet range. Although
ultraviolet detection can be extremely sensitive, its limitations include the fact that it is more
qualitative than quantitative in nature and the limitations on chromatographic solvent
conditions.32 Immunoassays for specific lipid species are used, but are limited because they are
not a direction detection method, are time-consuming and expensive, and are not available for all
lipids. Radiolabelling using 32P has long been a common method of lipid measurement.33 TLC or
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HPLC coupled to a radiation detector has been effectively used to analyze lipids, but
radiolabelling is labor intensive and is of a more qualitative than quantitative nature.
The rapid advances in mass spectrometric technology in the past two decades have
revolutionized the quantitative analysis of lipids. Mass spectrometry provides analysis of
compounds based on the mass-to-charge ratio (m/z) of charged particles. The general schematic
of mass spectrometric analysis of lipids proceeds in the following manner: the sample of interest
is ionized and vaporized, then separated based on m/z by electromagnetic fields. The ions are
then detected and processed to produce mass spectra that are used to provide accurate analysis.
Although there are many instrument variations of mass spectrometers, the equipment necessary
consists of a ion source, a mass analyzer, and a detector. The ion source is responsible for
producing ions from the vaporized sample which then proceed to the mass analyzer for sorting
by electromagnetic fields. A detector then measures the amount of ions present to produce a
mass spectrum.31
There are several ionization sources and mass spectrometer combinations commonly used
for lipid analysis. Matrix-assisted laser desorption ionization coupled to a time-of-flight
spectrometer (MALDI-TOF) is one method commonly used for lipid analysis.. During MALDITOF analysis, samples are mixed with a chemical matrix and dried onto a plate. A laser is then
used to ionize the sample, and the ions are introduced into a TOF mass spectrometer. The TOF
mass spectrometer measures the amount of time it takes from injection until the ions reach the
detector to produce a mass spectrum. Although MALDI-TOF provides very high sensitivity and
rapid sample analysis, matrices can often produce high background signal, making quantitative
measurements unreliable.34 MALDI-TOF is therefore used primarily for qualitative analysis.
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The most widely regarded methods for quantitative lipid analysis are direct injection into
a mass spectrometer, also called shotgun lipidomics, or injection into a mass spectrometer
following HPLC separation.31 A shotgun lipidomics approach involves a direct injection of
sample into the mass spectrometer, commonly using a syringe which is placed into a syringe
pump to introduce the sample into the spectrometer at a steady rate in order to provide a steady
signal.29 The sample then undergoes mass spectrometric analysis as outlined in the preceding
paragraph. While shotgun lipidomics is simple and quick, it is inappropriate for many samples
because it may cause mass spectrometer contamination, signal reduction, and ion interference. It
also does not efficiently separate lipid species and causes other issues that would make
quantitative analysis of specific species unreliable. Thus, shotgun lipidomics has primarily been
used as a screening tool for identification of lipids in a sample rather than for quantitation of
lipid species.34
The preferred method of lipid quantitation is injection into a mass spectrometer following
HPLC separation.29 Samples undergo extraction and HPLC separation as detailed previously and
are introduced into the mass spectrometer. This provides a sample which contains few
contaminants and thereby increases sample throughput for the instrument. It also provides the
ability to distinguish lipid species based on the retention time on the HPLC column.31 Coupling
of HPLC to a mass spectrometer capable of performing tandem mass spectrometric analysis has
become the common standard for accurate lipid quantitation. Tandem mass spectrometry
(MS/MS) is method of analysis that detects compounds based on the principle of measuring the
transition of a precursor ion of interest to a product fragment. A schematic demonstrating HPLC
ESI-MS/MS using a triple quadrupole mass spectrometer in multiple reaction monitoring mode
(MRM) is depicted in Figure 3. In this method of lipid quantitation, HPLC separation is
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performed and then the sample is introduced into the mass spectrometer. Ionization is performed
by an electrospray source which then focuses a tight beam of ions for progression into the Q0
quadrupole. The ions are taken via vacuum into the Q0 quadrupole where they are trapped for
progression into the Q1 quadrupole mass filter. The Q1 quadrupole scans and selects for a
precursor ion. The selected precursor ions progress from Q1 quadrupole mass filter into the Q2
collision cell where they are fragmented to create a product ion that is selected in the Q3 mass
filter. These product ions are then measured by the detector, and a spectrum is generated.
MS/MS uses the measurement of the distinct transition from precursor to product ion to provide
accurate quantitation for compounds of interest. By selecting the transitions corresponding to
individual lipid species and subspecies, HPLC ESI-MS/MS provides the most sensitive and
accurate lipid quantitation method commonly used in modern research.

13

Figure 3: HPLC ESI-MS/MS Diagram
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1.6

HPLC ESI-MS/MS Analysis of LPA
A variety of HPLC ESI-MS/MS methods have been developed to undertake LPA

measurements from tissue, blood, plasma, and serum samples, but most are specific for
separation and detection of LPA with little to no application in the detection of other lipid
classes. Additionally, most of these methods demonstrate poor quality peaks or inadequate
separation.35,36 Some methods have even required pre-separation of LPA using thin-layer
chromatography.37,38 There are also methodological issues for the extraction of LPA in these
reported protocols as most have relied on adapted Bligh-Dyer techniques with the use of very
low pH conditions, which may lead to the degradation of LPC to LPA and provide artificially
inflated LPA measurements.36, 39 Even after acidic extractions, the limit of quantitation for LPA
using these mass spectrometric methods have been in the low picomole or high femtomole range.
37,39

While this sensitivity is adequate for quantitation for the high LPA levels of in vivo

biological samples, greater sensitivity as well as a reliable, non-volatile pre-separation and
accurate extraction protocol are required for in vitro LPA measurements.

1.7

Project Objective
The objective of this study was to develop a HPLC ESI-MS/MS method for in vitro LPA

quantitation while avoiding the induction of artificially enhanced LPA levels from acidic
extraction protocols. Additionally, the separation and detection utilized for LPA was designed
for capability with the separation and detection of many other lipid classes. The method was
validated for in vitro use by demonstrating increased levels of LPA in autotaxin overexpressing
ovarian cancer cell lines. The biological role of these increased LPA levels was further validated
using previously established proliferation and migration assays for measuring the levels of this

15

bioactive lipid. This novel HPLC ESI-MS/MS method will provide researchers with the ability to
measure in vitro LPA levels as well as provide a more sensitive and accurate method for LPA
quantitation in biological samples.
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Materials and Methods

2.1

Materials
SKOV3-Zeo, SKOV3-ATX, DOV13-Zeo, and DOV13-ATX cell lines were established

by transfection of SKOV3/DOV13 cells with pcDNA3.1/Zeo or pcDNA3.1/Zeo-ATX (kindly
provided by J Aoki, Kawasaki Medical School, Okayama, Japan) The transfected cells were
selected with zeocin (500 ng/ml). Individual zeocin-resistant colonies were isolated by ring
cloning and expanded sequentially in 24-well, 6-well and 60-mm plates. Expression of ATX
protein was confirmed by immunoblotting. The ATX-positive clones were maintained as stable
lines in RPMI (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 2%
penicillin/streptomycin (BioWhittaker). SKOV3-Zeo and SKOV3-ATX clonal cell lines were
cultured under 5% CO2 at 37°C with routine passage every 2-3 days. LPA standards (14:0, 16:0,
17:0, 18:0, 18:1, 20:4) were purchased from Avanti Polar Lipids (Alabaster, AL, USA).
Ammonium formate (Fluka) were purchased from Sigma-Aldrich (St. Louis, MO, USA). HPLC
grade methanol, HPLC grade chloroform and ACS grade formic acid (EMD Chemicals) were
purchased from VWR (Bridgeport, NJ, USA). Cellular Proliferation Reagent WST-1 was
purchased from Roche (Indianapolis, IN, USA).

2.2

HPLC ESI-MS/MS Conditions
LPA subspecies were separated using a Kinetex 2.6u C18 100Å 50 x 2.1 mm reverse

phase column on a Shimadzu 20-AD Series HPLC and subjected to mass spectrometric analysis
using a ABSCIEX 4000 QTRAP. Mass spectrometry parameters were as follows: PolarityNegative, Ion Source: Electrospray, Q1 Resolution: Low, Q3 Resolution: Unit, Collision
Activated Dissociation: High, MCA: No, Curtain Gas: 15.0 psi, Ion Source Temperature:
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400.0°C, Nebulizer Gas: 30.0 psi, Turbo Gas: 70.0 psi, Interface Heater: On, Ion Spray Voltage 4500.0 V, Collision Cell Exit Potential: -9.0. MRM transitions with corresponding declustering
potentials, collision energies and collision exit potentials are listed in Table 3.
HPLC conditions were as follows: Total Flow: 300 µl/min, Injection Volume: 10 µl,
Column Oven: 50.0°C. Solvents for reverse phase HPLC separation were: Solvent A, 58:41:1
methanol:water:formic acid and solvent B, 99:1 methanol:formic acid. Both solvents contained 5
mM ammonium formate. Solvent conditions for HPLC separations were: 100% Solvent A from
0-1 minute, linear increase in minutes 1-7 from 100% Solvent A to 100 % Solvent B, 100%
Solvent B from minutes 7-8, immediate switch from 100% Solvent B to 100% Solvent A at
minute 8, 100% A for minutes 8-10.

2.3

1% FBS Experiments
SKOV3-Zeo, SKOV3-ATX, DOV13-Zeo, and DOV13-ATX cells were plated in 10 cm

dishes and grown to 80% confluency in 10% FBS supplemented RPMI. Cells were transferred to
1% FBS supplemented media overnight. Media was aliquoted into glass screw-top vials and
stored at -20°C until HPLC ESI-MS/MS analysis and biological assays could be performed.
Cells were harvested in 200 µl cold PBS. Results for HPLC ESI-MS/MS analysis were
normalized to microgram protein from harvested cells using a Bradford assay.

2.4

LPA Extraction Procedures
A modified Bligh-Dyer method was used to extract LPA from sample media. The

extraction protocol was as follows: 100 µl of sample media, 1 ml chloroform, 500 µl methanol,
250 µl dH2O and 100 fmol 17:0 LPA standard were combined, vortexed, sonicated, and then
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centrifuged at 4000 rpm for 10 minutes. The aqueous (top) layer was transferred to a clean glass
tube, dried and resuspended in 100 µl methanol for mass spectrometry analysis and is
represented as "Bligh-Dyer Aqueous". Organic (bottom) layer from the same extraction was
transferred to a separate clean glass vial, dried and resuspended in 100 µl methanol for mass
spectrometry analysis and is represented as "Bligh-Dyer Organic". After a separate Bligh-Dyer
extraction was performed, the aqueous and organic layers were combined, dried and resuspended
in 100 µl methanol for mass spectrometry analysis and are represented as "Bligh-Dyer"
A modified Folch method was also utilized for LPA extraction. The protocol was as
follows: 200 µl sample + 2.5 ml chloroform + 1.25 ml methanol + 250 µl dH2O and 100 fmol
17:0 LPA standard were combined, vortexed, sonicated, and then centrifuged at 4000 rpm for 10
minutes. The aqueous (top) layer was transferred to a clean glass tube, dried and resuspended in
100 µl methanol for mass spectrometry analysis and is represented as "Folch Aqueous". Organic
(bottom) layer from the same extraction was transferred to a separate clean glass vial, dried and
resuspended in 100 µl methanol for mass spectrometry analysis and is represented as "Folch
Organic". After a separate Folch extraction was performed, the aqueous and organic layers were
combined, dried and resuspended in 100 µl methanol for mass spectrometry analysis and are
represented as "Folch"

2.5

Cellular Migration Assay
Cellular migration was measured in transwell chambers (pore size 8.0 µm; Corning

Incorporated, Corning, NY) according to protocol in previous literature.40 In short, transwells
were coated with 0.1 mg/ml collagen and placed in lower chamber containing media from 1%
FBS experiments detailed above. SKOV3-Zeo cells suspended in serum-free RPMI containing

19

0.1% fatty acid-free BSA were added to the upper chamber at 2.5 x 104 cells/well. Cells were
allowed to migrate for 6 hours under 5% CO2 at 37ºC. Top of insert filter surface was washed
with PBS and then stained with 0.1% crystal violet in methonal for 10 minutes. Filter surface
was washed three times with PBS, and non-migrated cells were removed from the top filter
surface with a cotton swab. Migrated cells were stained by the crystal violet and counted under a
microscope.

2.6

Cellular Proliferation Assay
Cellular proliferation was measured using WST-1 based colorimetric assay. SKOV3-Zeo

cells (5 x 105) were plated in five six-well plates and allowed to attach for 12 hours. 12 hours
after plating, WST-1 reagent (200 µl) was added to four wells of one plate for reading of
baseline attachment of SKOV3-Zeo cells. WST-1 reagent was allowed to incubate for 1 hour and
absorbance was read at 450 nm with blank media absorbance used as background subtraction.
After allowing cells to attach to the plate overnight, wells were washed once with PBS and 2 ml
of conditioned media from the 1% FBS experiments was added to wells. Absorbance at 450 nm
was measured using WST-1 reagent at 36 and 48 hours post-baseline reading. Cellular
proliferation was calculated by subtracting the absorbance of blank media and average
absorbance of 12 hour baseline measurement.
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Results

3.1

Retention Time Markers and Linear Signal Response Show Increased HPLC ESIMS/MS Sensitivity for LPA Quantitation

Previous HPLC ESI-MS/MS methods have been limited in sensitivity allowing only for
quantification of LPA from biological samples such as tissue, blood, plasma, or serum. The goal
of this study was to produce an HPLC ESI-MS/MS method with a high degree of sensitivity to
quantify LPA levels from cell culture. In this regard, distinct fragmentation patterns were
required for determination of optimal mass spectrometer parameters for the detection of LPA
subspecies (Figure 4). Quantitative optimization for the transition of precursor to product ions
supplied the optimal ABSCIEX 4000 QTRAP parameters that are detailed in Table 3. There
were three common product ions produced upon fragmentation of LPA subspecies: 79 m/z representing the fragmentation of the phosphite (PO3-3) from the sn-3 position, 97 m/z representing the fragmentation of the phosphate (PO4-4) from the sn-3 position, and 153 m/z representing the cyclical glycerol backbone produced upon fragmentation. The 153 m/z product
ion was chosen for method development as it is the product ion common to all subspecies that
was produced with the highest intensity (Figure 4).
Reverse phase HPLC separation prior to ESI-MS/MS provided the ability to easily and
accurately distinguish LPA subspecies in relation to specific retention times. Several HPLC
solvent conditions were investigated for accurate separation. The traditional HPLC solvents for
LPA analysis provided insufficient elution from the fused-core column and insufficient
separation among subspecies (data not shown).37, 39, 41, 42 In order to increase sample throughput,
the HPLC solvent system used by the Chalfant laboratory for sphingolipid analysis was
investigated for LPA analysis. Multiple variations of HPLC solvent gradients for this system
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were attempted, but the best separation was provided by the solvent system and gradient detailed
in Figure 5. Distinct chromatograms were produced (Figure 6) to allow accurate identification of
LPA species related to specific HPLC retention times (Table 3). Peak assignments were initially
determined by the analysis of indicated LPA standards using the MRM transitions and mass
spectrometry parameters detailed in Table 3. Since there are no commercially available standards
for 18:2 LPA and 22:6 LPA, relative retention times were calculated based upon the retention
times for experimentally validated standards.
To investigate the sensitivity limits of this novel HPLC ESI-MS/MS method, a standard
mixture of 14:0 LPA, 16:0 LPA, 17:0 LPA, 18:0 LPA, 18:1 LPA and 20:4 LPA was analyzed in
concentrations from 10 fmols to 1 pmol per injection, and the signal response was measured as
the area under the peak. When the results were plotted as signal response versus LPA
concentration, a linear relationship was generated with correlation coefficients above 0.999
(Figure 7A). When the results were plotted as a log-log plot of signal response versus LPA
concentration, a linear relationship was generated with correlation coefficients above 0.997
(Figure 7B). Intra-day and inter-day precision and accuracy of QC samples were within
acceptable range (Table 4). The method produced a lower limit of quantitation (five times signal
to noise ratio) of 10 fmol per injection for each chain length. This lower limit of quantitation
represents a minimum of a five-fold increase in sensitivity from the most recent HPLC ESIMS/MS LPA method and fifteen-fold increase in the remaining mass spectrometric reports in the
literature for LPA analysis.37,43
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Figure 4: Fragmentation patterns are required for development of a mass spectrometric method
for the analysis of LPA subspecies. Direct infusion of dilute standards into ABSCIEX
4000QTRAP provides distinct fragmentation patterns of precursor to product ions for each LPA
subspecies. The 153.0 m/z product ion represents the cyclical glycerol backbone produced by
fragmentation of precursor LPA ions and is common to all LPA subspecies. The 153.0 m/z
product ion is therefore used during MRM analysis.
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Precursor Ion

Product Ion

Retention Time

(m/z)

(m/z)

DP

CE

EP

(min)

14:0 LPA

381.3

152.7

-70.0

-26.0

-11.0

5.47

16:0 LPA

409.3

152.7

-60.0

-30.0

-12.0

6.44

17:0 LPA

423.3

152.7

-80.0

-30.0

-11.0

6.81

18:2 LPA

433.3

152.7

-80.0

-30.0

-10.0

6.14

18:1 LPA

435.3

152.7

-80.0

-30.0

-10.0

6.67

18:0 LPA

437.3

152.7

-60.0

-30.0

-12.0

7.15

20:4 LPA

457.3

152.7

-70.0

-30.0

-12.0

6.20

22:6 LPA

481.3

152.7

-70.0

-30.0

-12.0

6.14

Table 3: ABSCIEX 4000 QTRAP mass spectrometer settings and retention times for reverse
phase chromatographic separation of LPA species as described in Materials and Methods. DP declustering potential, CE - collision energy, EP - entrance potential.
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Figure 5: A novel solvent system allows for reverese phase HPLC seperation of LPA subspecies
at distinct retention times. A Kinetex 2.6u C18 100A 50 x 2.1 mm reverse phase column on a
Shimadzu 20-AD Series HPLC provides optimal separation using the following HPLC
parameters: Total Flow: 300 µl/min, Injection Volume: 10 µl, Column Oven: 50.0°C. Solvent
conditions for reverse phase HPLC separation are: Solvent A, 58:41:1 methanol/water/formic
acid and Solvent B, 99:1 methanol/formic acid. Both solvents will contain 5 mM ammonium
formate. Solvent gradient for HPLC separation is: 100% Solvent A from 0-1 minute, linear
increase in minutes 1-7 from 100% Solvent A to 100 % Solvent B, 100% Solvent B from
minutes 7-8, immediate switch from 100% Solvent B to 100% Solvent A at minute 8, 100% A
for minutes 8-10.
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Figure 6: Retention time standards are required for unambiguous peak assignment in the
quantitation of LPA species during reverse phase HPLC ESI-MS/MS analysis. An internal
standard mixture of commercially available LPA standards produces distinct MRM
chromatograms for 14:0 LPA, 16:0 LPA, 17:0 LPA, 18:1 LPA, 18:0 LPA and 20:4 LPA for the
purpose of unambigious peak assignment during HPLC ESI-MS/MS data analysis.
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Panel A

Panel B

Figure 7: The method of detection for LPA species shows a linear response in the range from 10
fmol to 1 pmol for LPA standards. An internal standard mixture of 14:0 LPA, 16:0 LPA, 17:0
LPA, 18:0 LPA and 20:4 LPA was made in concentrations varying from 10 fmol/injection to 1
pmol/injection. (A) . The results were plotted as signal response (area under the peak) versus
amount standard in fmol/injection. Data is the average of four separate sample injections ±
SEM. (B) The results were plotted as log10 of signal response (area under the peak) versus log10
fmol of standard per injection in a log-log plot. Data is the average of four separate sample
injections ± SEM.
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LPA Species

Nominal
Intra-day precision and accuracy
Concentration (nM) Mean (n = 4) (nM) Mean accuracy (%) CV (%)

Inter-day precision
Mean (n = 4 days) (nM) CV (%)

14:0 LPA

20
40
80
100

20.7
41.8
85.4
101.8

103.7
104.5
106.7
101.8

2.3
6.8
2.7
10.3

21.4
42.1
81.9
98.4

7.0
10.0
8.1
11.7

16:0 LPA

20
40
80
100

21.4
40.6
75.1
96.9

107.2
101.5
93.8
96.9

3.3
5.8
4.9
7.1

20.5
41.4
76.0
97.2

8.8
7.5
7.2
8.3

17:0 LPA

20
40
80
100

21.7
42.3
80.1
103.4

108.7
105.9
100.1
103.4

6.6
4.1
6.3
3.2

21.7
42.4
81.8
101.0

4.8
6.1
5.5
6.6

18:1 LPA

20
40
80
100

20.7
39.8
76.3
95.8

103.3
99.4
95.4
95.8

1.9
5.5
3.8
3.6

20.6
41.2
82.0
103.9

9.3
5.6
6.9
8.3

18:0 LPA

20
40
80
100

22.3
43.5
79.9
100.3

111.7
108.7
99.9
100.3

4.1
3.5
3.7
3.9

21.6
42.1
82.5
100.2

6.4
5.6
4.3
4.7

20:4 LPA

20
40
80
100

21.4
40.4
75.2
91.2

107.2
101.1
94.1
91.2

10.3
5.6
6.0
3.0

20.0
41.3
83.2
99.3

11.7
10.7
10.6
9.8

Table 4: Intra-day and Inter-day Precision and Accuracy
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3.2

Non-acidified Extraction Methods Produce Quantifiable LPA Levels Without LPC
Degradation

Most reported HPLC ESI-MS/MS methods for quantitation of LPA have relied on
extraction methods that required highly acidic treatments. These acidic conditions may
contribute to the artificial conversion of LPC to LPA, and thereby lead to LPA measurements
that are not characteristic of actual sample levels.36, 39 To address this issue, a number of
extraction techniques without acidic treatment were tested on conditioned media samples. First, a
direct media sample injection into the HPLC following polarity adjustment to starting HPLC
conditions was tested. This extraction method proved to be insufficient due to a lack of sample
concentration step during extraction (data not shown). Next, a simple lysophospholipid
extraction that consists of a single methanol solvent dilution and single step of centrifugation was
utilized as previously reported.44 While this extraction was suitable for LPA extraction of in vivo
samples, it was unsuccessful at providing sufficient recovery of the minute levels of LPA from in
vitro samples because this protocol also lacked a sample concentration step (data not shown). A
solid-phase extraction protocol utilizing a reversed phase silica based column was also tested but
did not provide sufficient results due to an inability to efficiently remove LPA from the column
during the final elution step (data not shown). Finally, two non-acidified liquid-liquid extractions
termed modified Bligh-Dyer and modified Folch extractions were tested and showed to provide
reliable recovery of LPA at levels above the limits of quantitation (Figure 8). Importantly, the
Folch extraction technique demonstrated a more reliable recovery of LPA with the combined
organic and aqueous fractions approximately equaling the total Folch recovery (Figure 8).
Therefore, the total Folch extraction was used throughout the remainder of the manuscript due to

29

its consistent recovery, simple protocol, and lack of producing artificial LPA contamination
under acidic conditions.
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Figure 8: Non-acidic extraction methods for in vitro LPA quantitation show that organicaqueous phase break protocols provided sufficient recovery for HPLC ESI-MS/MS analysis for
1% FBS overnight treated DOV13-Zeo cells. BD - combined layers of Bligh-Dyer, BD Aqueous
- aqueous layer of Bligh-Dyer, BD Organic- organic layer of Bligh-Dyer, Folch - combined
layers of Folch, Folch Aqueous - aqueous layer of Folch, Folch Organic - organic layer of Folch.
Extraction protocols are detailed in Materials and Methods. Data represents n = 3 ± SEM.
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3.3

Autotaxin Overexpression Induces an Increase in Specific LPA Species
With the optimal extraction procedure for LPA determined, the protocol was fully

operational for validation using biological applications. In this regard, we chose to examine the
production of LPA in autotaxin-overexpressing cells as compared to vector control cells. Since
ovarian cancer has been widely established to have increased LPA dysregulation, ovarian cancer
cell lines SKOV3 and DOV13 and their corresponding autotaxin clones were analyzed. Figure
9A shows that the 16:0, 18:1, 18:2, 18:0, and 20:4 LPA subspecies were significantly increased
in the media from SKOV3-ATX cells, but importantly, the 22:6 LPA subspecies remained
relatively unchanged. Similarly, comparison of LPA subspecies in media from DOV13-Zeo and
DOV13-ATX showed an increase in the 16:0, 18:1, and 18:0 LPA subspecies with little or no
change among the 14:0, 20:4, and 22:6 LPA subspecies (Figure 10A). Hence, autotaxin increases
the levels of specific chain lengths of LPA. Furthermore, the total levels of LPA increased twofold in media from autotaxin-overexpressing cells in both cell lines studied, as indicated in
Figures 9B and 10B.
Prior to the development of this HPLC ESI-MS/MS method for quantitation of LPA from
cell culture, quantitation of LPA production have relied on comparisons to the effect of
exogenously introduced LPA on biological assays such as cellular migration and
proliferation.40,45 Therefore, the observed increases in LPA levels produced by autotaxin
overexpression as assayed by HPLC ESI-MS/MS were compared to the biological effect of these
increased levels of LPA cellular migration and proliferation. Specifically, media from either
SKOV3-Zeo or SKOV3-ATX was used as a chemoattractant in cellular migration assays. Media
from SKOV3-ATX produced a two-fold increase in cellular migration when compared to media
from SKOV3-Zeo, which correlated to the increase in LPA levels measured by HPLC ESI32

MS/MS (Figure 11). To further validate the increase in LPA levels in SKOV3-ATX media, the
effect of SKOV3-ATX and SKOV3-Zeo media on cellular proliferation was measured. Media
from autotaxin overexpressing cells induced an increased in cellular proliferation as compared to
SKOV3-Zeo media, which also correlated to the total increase in LPA levels measured by HPLC
ESI-MS/MS (Figure 12).
Migration and proliferation studies were also done with conditioned media from DOV13Zeo and DOV13-ATX cells to validate the HPLC ESI-MS/MS analysis detailed in Figure 10.
The approximate two-fold increase of cellular migration of SKOV3-Zeo cells using conditioned
media from DOV13-Zeo and DOV13-ATX as chemoattractants correlated to the two-fold
increase of total LPA levels as determined by HPLC ESI-MS/MS analysis (Figure 13). However,
the SKOV3-Zeo cellular proliferation assays using conditioned media from DOV13-Zeo and
DOV13-ATX showed no increase in cellular proliferation (Figure 14). This result shows that the
HPLC ESI-MS/MS method developed in this study is superior to biological assays currently in
use.
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Panel A

Panel B

Figure 9: Comparison of control vector SKOV3 cells versus autotaxin-overexpressing clones
show increased levels of LPA in autotaxin-overexpressing cell lines. (A) HPLC ESI-MS/MS
analysis of LPA subspecies shows increases in 16:0, 18:2, 18:1, 18:0, and 20:4 LPA levels, but
not 22:6 LPA. Data represents n = 3 ± SEM. (B) HPLC ESI-MS/MS analysis detailed in (A)
shows an approximate two-fold increase in total LPA levels between control vector and
autotaxin-overexpressing cells. Data represents n = 3 ± SEM. p-values were calculated as
student's t-test using SigmaPlot v. 12.0 (SyStat).
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Panel A

Panel B

Figure 10: Comparison of control vector DOV13 cells versus autotaxin-overexpressing clones
show increased levels of LPA in autotaxin-overexpressing cell lines. (A) HPLC ESI-MS/MS
analysis of LPA subspecies shows increases in 16:0, 18:1, 18:0, and 20:4 LPA levels, but not
14:0 or 22:6 LPA. Data represents n = 3 ± SEM. (B) HPLC ESI-MS/MS analysis detailed in (A)
shows an approximate two-fold increase in total LPA levels between control vector and
autotaxin-overexpressing cells. Data represents n = 3 ± SEM.
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SKOV3 –
Zeo Media

SKOV3 –
ATX Media

Panel B

Figure 11: Conditioned media from SKOV3 autotaxin-overexpressing clones correspond to
increased cellular migration of SKOV3-Zeo cells when compared to conditioned media from
control vector cell lines. Media from overnight 1% FBS experimental protocol was used as a
chemoattractant for cellular migration assay as detailed in Materials and Methods. (A) Images of
migrated cells show increased SKOV-Zeo cellular migration using conditioned media from
autotaxin-overexpressing cell line. (B) Calculations show that increases in migration correspond
to total LPA levels measured by HPLC ESI-MS/MS analysis. Data represents n = 4 ± SEM. pvalues were calculated as student's t-test using SigmaPlot v. 12.0 (SyStat).
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36 Hour

48 Hour

SKOV3 –
Zeo
Media

SKOV3 –
ATX
Media

Panel B

Figure 12: Conditioned media from SKOV3 autotaxin-overexpressing clones is associated with
increased SKOV3-Zeo cellular proliferation when compared to conditioned media from control
vector cell line. (A) Images of cell growth at corresponding time points show increased SKOVZeo cellular proliferation. (B) Calculations show that increases in proliferation correspond to
total LPA levels measured by HPLC ESI-MS/MS analysis. Data represents n = 5 ± SEM. pvalues were calculated as student's t-test using SigmaPlot v. 12.0 (SyStat).
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DOV13 –
Zeo Media

DOV13 –
ATX
Media

Panel B

Figure 13: Conditioned media from DOV13 autotaxin-overexpressing clones correspond to
increased cellular migration of SKOV3-Zeo cells when compared to conditioned media from
control vector cell lines. (A) Images of migrated cells show increased SKOV-Zeo cellular
migration using conditioned media from autotaxin-overexpressing cell line. (B) Calculations
show that increases in migration mimic the increased total LPA levels measured by HPLC ESIMS/MS analysis. Data represents n = 4 ± SEM. p-values were calculated as student's t-test using
SigmaPlot v. 12.0 (SyStat).
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36 Hour

48 Hour

DOV13 –
Zeo
Media

DOV13 –
ATX
Media

Panel B

Figure 14: Conditioned media from DOV13 autotaxin-overexpressing clones does not
correspond to increased SKOV3-Zeo cellular proliferation when compared to conditioned media
from control vector cell line. (A) Images of cell growth at corresponding time points show no
increase in SKOV-Zeo cellular proliferation. (B) Calculations show that, unlike SKOV3-ATX
conditioned media, DOV13-ATX conditioned media does not cause an increase in SKOV13-Zeo
cellular proliferation. Data represents n = 5 ± SEM. p-values were calculated as student's t-test
using SigmaPlot v. 12.0 (SyStat).
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Discussion

4.1

Necessity for this Novel HPLC ESI-MS/MS Method
The few reported methods for measuring endogenous LPA in vitro have suffered from a

multitude of problems, such as inability to distinguish LPA species, a labor intensive nature, and
high limits of detection. For example, some previous studies have even relied on thin-layer
chromatography for pre-separation, a highly labor intensive and mainly qualitative protocol, for
measuring autotaxin activity and subsequent LPA production in vitro.38 Recently, HPLC ESIMS/MS has been established as a reliable method for LPA quantitation from biological samples,
but the significant limitations of these methods have made in vitro analysis unfeasible. In this
study, we have developed a HPLC ESI-MS/MS method with increased sensitivity to resolve
these issues and provide researchers the ability to make in vitro LPA quantitation possible in
conjunction with quantitative measurements of other lipid classes.

4.2

Advantages of HPLC Conditions Utilized in this Study
Prior to this study, many of the publications utilizing HPLC ESI-MS/MS method

development for LPA measurement suffer from undesirable HPLC conditions. For example, one
report demonstrated what was termed "unidentified peaks" during chromatographic separation.37
The HPLC conditions reported here allow for a more reliable identification of LPA species by
the elimination of these unidentifiable peaks. This HPLC method also does not utilize
undesirable solvent conditions. For example, the highly acidic solvents used by some methods
may result in on-column degradation of LPA and artificial conversion of LPC to LPA.35 Also, the
highly organic solvents reported by other groups can affect the lifetime of the HPLC seals and
are not functional for analysis of other lipid classes in the same sample run.36,39 Use of such lipid
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class specific HPLC methods significantly reduces the amount of data acquired from a single
sample. The solvent system used in this study has previously been established for the study of
sphingolipids, particularly ceramide, ceramide-1-phosphate, sphingosine, and sphingosine-1phosphate.46 Other HPLC solvent systems reported for LPA, including the most recent HPLC
ESI-MS/MS method with highest sensitivity until this report, have the potential for ion
suppression due to the inclusion of triethyl ammonium acetate as a modifier.43 This suppression
will produce the requirement of regular and thorough cleaning of the instrument before further
analysis of other lipid classes. The need to change solvent systems to analyze the different lipid
species also significantly increases valuable instrument time, thereby decreasing sample
throughput. The HPLC ESI-MS/MS method in this study also utilizes solvent conditions that do
not cause contamination and are capable of being used for sphingolipid analysis. Hence, this new
HPLC ESI-MS/MS method for LPA not only overcomes the undesirable HPLC conditions but
also uses chromatographic separation that allows for other lipids to be efficiently analyzed
during the same sample run.

4.3

Advantages of LPA Extraction Method Utilized in this Study
An easy and reliable extraction method for LPA analysis was determined. Prior to this

study, numerous extraction protocols have been published for the separation of LPA from
biological samples, but early methods used thin-layer chromatographic separation as the initial
basis of separation, and subsequent protocols have utilized a modified form of Bligh-Dyer lipid
extraction where the optimal recovery is obtained using highly acidic conditions.37,38 These acidic
conditions have been shown to cause conversion of LPC to LPA during extraction and thereby
provide inaccurate and artificial measurements.36,47 Water-saturated butanol liquid-liquid
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extraction methods have proven to be efficient, but are quite labor intensive.39,47. The extraction
method utilized in this study is a simple, efficient, organic-aqueous phase break separation that
requires minimal labor, minimizes artificial LPA measurements, and provides sufficient recovery
for LPA quantitation.

4.4

Increased Sensitivity Provides the Ability for Quantitation of in vitro LPA Levels
The method described herein provides a highly sensitive assay for the quantification of

LPA levels from in vitro experiments. An increase in HPLC ESI-MS/MS sensitivity was
necessary to quantify LPA subspecies levels from in vitro samples as other in vitro LPA
quantitation methods had significant sensitivity limitations. The most sensitive HPLC ESIMS/MS method previously reported for LPA subspecies quantitation has a lower limit of
quantitation of 54 femtomoles on-column.43 The method described in this study achieves a lower
limit of quantitation of 10 femtomoles on-column . Hence, this represents a five-fold increase in
sensitivity levels for HPLC ESI-MS/MS analysis. Furthermore, other reported studies could only
assay one subspecies of LPA even when attempting to artificially induce LPA production by
LPC treatment.48 This reported method also suffered from the same acidic extraction conditions
as previously published protocols, limiting even conclusions for this one LPA subspecies.48 The
increased sensitivity of the HPLC ESI-MS/MS method developed in this study will provide
researchers with the ability to easily and accurately quantify all LPA subspecies levels in vitro.
Furthermore, the method described in this study was the first to be validated by traditional
biological assays.
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4.5

Conclusions and Future Directions
Measurement of LPA in vitro has proven to be unreliable until the development of the

HPLC ESI-MS/MS method described herein. Previous HPLC ESI-MS/MS methods have
focused on biological samples, which contain high levels of LPA, and which have also suffered
from unfavorable HPLC conditions, hazardous and inaccurate extraction protocols, and
inadequate sensitivity levels. This new HPLC ESI-MS/MS method will offer researchers a
valuable tool for determination of the activities of LPA subspecies for the purpose of delineating
biological mechanisms and pre-clinical drug development for diseases such as diabetes,
atherosclerosis, and cancer. The increased sensitivity levels will also provide clinicians with
better ability to quantitate LPA with the goal of early detection of disease states. Overall, the
HPLC ESI-MS/MS method presented in this study supplies a new tool for further exploration of
the biological functions of LPA.
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